^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Junction Adenocarcinoma

    Related cancers:
    1d
    Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Dec 2026 --> May 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan)
    2d
    KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=161, Active, not recruiting, ModernaTX, Inc. | N=242 --> 161 | Trial completion date: Aug 2027 --> Nov 2027 | Trial primary completion date: Aug 2027 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)
    2d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    2d
    A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=542, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF mutation • HER-2 negative • RAS mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Yervoy (ipilimumab) • SAR445877 • muzastotug (ADG126)
    2d
    NCI 10211: Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MSI (Microsatellite instability)
    |
    HER-2 positive • TP53 mutation • MSI-H/dMMR
    |
    FoundationOne® CDx
    |
    irinotecan • berzosertib (M6620)
    2d
    Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=164, Recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CLDN18 (Claudin 18)
    |
    HER-2 positive • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • MET exon 14 mutation • MET overexpression • MET mutation
    |
    Ensacove (ensartinib) • pamvatamig (MCLA-129)
    2d
    A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • 5-fluorouracil • Stivarga (regorafenib) • oxaliplatin • leucovorin calcium
    2d
    LUCERNA: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (clinicaltrials.gov)
    P3, N=500, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2029 --> Sep 2028 | Trial primary completion date: Dec 2029 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CLDN18 (Claudin 18)
    |
    MSI-H/dMMR • HER-2 negative
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)
    2d
    GASTROBRAIN: Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer (clinicaltrials.gov)
    P=N/A, N=230, Active, not recruiting, Blokhin's Russian Cancer Research Center
    New trial
    3d
    A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=422, Not yet recruiting, Akeso
    New P3 trial
    |
    capecitabine • oxaliplatin • Kaitanni (cadonilimab)
    3d
    Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. (PubMed, J Clin Oncol)
    Trastuzumab rezetecan showed tolerable safety and preliminary efficacy in HER2-expressing advanced GC/GEJ and CRC.
    P1 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811)
    3d
    Expression of CLDN18.2 in Invasive Mucinous Adenocarcinomas of the Lung. (PubMed, Cancer Diagn Progn)
    Its expression was rarely observed in other histological types of lung cancer. CLDN18.2 is frequently expressed in IMAs but rarely in other major lung cancer subtypes, suggesting that zolbetuximab may represent a promising targeted therapy for IMA.
    Journal
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive
    |
    Vyloy (zolbetuximab-clzb)